Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00451984

Acronym

HEPVACHIV

Enrollment

Registered

2007-03-26

Start date

2007-03-31

Completion date

Unknown

Last updated

2007-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Hepatitis A, Hepatitis B

Keywords

interleukin-2, vaccination, treatment experienced

Brief summary

The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.

Interventions

BIOLOGICALTwinrix

BIOLOGICALinterleukin-2

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion criteria

* Prior hepatitis A or B

Design outcomes

Primary

Measure	Time frame
Antibody response to hepatitis A and hepatitis B	—

Countries

Denmark

Contacts

Primary ContactHenrik Nielsen, MD, DMSci

henrik.nielsen@rn.dk+45-99326525

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026